Drug intelligence / Profile preview

SR-3

Development stage: Unknown
Lead developer: Seraxis
Modality: Small Molecules

Overview

SR-3 is a preclinical-stage fatty acid compound consisting of a mixture of linoleic and alpha-linolenic acids (free non-esterified unsaturated fatty acids). Developed by Seraxis, Inc., it is primarily being investigated for the treatment of diabetes mellitus and metabolic diseases. Beyond endocrinology, SR-3 has demonstrated neuroprotective properties in animal models, showing efficacy comparable to carbamazepine in controlling pentylenetetrazol (PTZ)-induced seizures and preventing stress-induced elevations in cortisol and cholesterol. Its mechanism involves modulating the physiological consequences of intense stress, potentially protecting hippocampal structures from corticosteroid-mediated damage, which suggests potential applications in cognitive decline and Alzheimer's disease.

Other names: linoleic acid + alpha-linolenic acid

Beyond the preview

Go deeper on SR-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-3.

Explore the full profile